|Bid||0.1050 x 5000|
|Ask||1.5000 x 500|
|Day's Range||0.0810 - 0.0900|
|52 Week Range||0.0800 - 0.5500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
EATONTOWN, NJ / ACCESSWIRE / April 2, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products ...
During fiscal 2019, CRYO began transitioning its FDA registered laboratory facility from tissue bank status to full biologics manufacturer by upgrading our main laboratory facility in New Jersey. Additionally, the Company filed its first Investignational New Drug (IND) Application with the FDA, for its ATCELL™ adipose derived mesenchymal cellular therapy product, a major milestone for the Company and patients. As we enter 2020, our standardized stem cell processing platform provides all individuals with a cost effective "wellness" platform for their current or future regenerative medicine and/or cosmetic needs.
The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel suffering ...
EATONTOWN, NJ / ACCESSWIRE / September 18, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, announced today that it has submitted its first Investigational New Drug Application application for its ATCell™ product (the "Investigational Drug"), to the U.S. Food and Drug Administration (FDA). The FDA's acceptance for review of American CryoStem's IND application is a significant milestone for the Company and represents a meaningful step forward in the treatment of patients suffering from Post Concussion Syndrome ("PCS"), and for the advancement of Regenerative Medicine.
EATONTOWN, NJ / ACCESSWIRE / September 11, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has contracted with BioSolutions Clinical Research Center, LLC. (“BioSolutions”) to conduct a clinical study (“Study”) of ATCELL™ (“Investigational Drug”) as part of a single center study under a protocol entitled: ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes during CRYOs Investigational New Drug (IND) filing with the FDA. BioSolutions located in La Mesa, CA.
The IRCM is a non-profit 501(c)(3) registered with the U.S. Department of Health and Human Services (HHS) and is qualified under the regulations to provide the required oversight. The FDA requires oversight of all IND clinical studies by an IRB.